Literature DB >> 2994495

Compartmented pyruvate in perfused working heart.

R Bünger.   

Abstract

Pyruvate compartmentation and lactate dehydrogenase (LDH) were studied in isolated perfused working guinea pig hearts. The mean intracellular pyruvate (Pyr) contents increased with perfusate Pyr (0-2 mM) but varied only slightly with glucose (0-10 mM) and additional insulin (0.04-5 U/l), respectively. With 5-10 mM glucose plus 5 U/l insulin, but not with Pyr or lactate (Lac) as substrates, a near equilibrium between the LDH and the glycerol-3-phosphate dehydrogenase seemed to exist. Evidence for an inhibitory effect of Pyr on the activity of the LDH system of the perfused hearts was not obtained. With [U-14C]glucose as sole substrate, the specific activity of coronary venous Lac was near half that of precursor glucose. 14CO2 production was thus in quantitative agreement with rates of pyruvate oxidation that were determined as glucose uptake minus (Pyr + Lac) release. In contrast, with 0.2 mM [1-14C]Pyr plus 5 mM glucose, the ratio of 14CO2 production to specific activity of Lac overestimated Pyr oxidation judged from myocardial substrate balances and O2 uptake, respectively; here, at least three pools of [14C]HCO-3 and [14C]lac, respectively, were kinetically demonstrable during washout of trace amounts of 14C-labeled Pyr. Evidently, the specific activity of Lac was equivalent to that of mitochondrial oxidized Pyr provided [14C]glucose was the sole or major precursor of cellular pyruvate. However, exogenously applied [1-14C]Pyr of high specific activity seemed to induce intracellular formation of both a highly and lowly labeled Pyr; the latter Pyr compartment did not seem in ready equilibrium with the cell physiologically prevailing highly labeled Pyr pool.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994495     DOI: 10.1152/ajpheart.1985.249.3.H439

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Tracer kinetics analysis of the extracellular spaces in saline perfused hearts.

Authors:  M K Aliev; A N Khatkevich; V G Tsyplenkova; F E Meertsuk; V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

2.  Insulin-like effects of a physiologic concentration of carnitine on cardiac metabolism.

Authors:  R L Rodgers; M E Christe; G C Tremblay; J R Babson; T Daniels
Journal:  Mol Cell Biochem       Date:  2001-10       Impact factor: 3.396

3.  Co-Polarized [1-13C]Pyruvate and [1,3-13C2]Acetoacetate Provide a Simultaneous View of Cytosolic and Mitochondrial Redox in a Single Experiment.

Authors:  Gaurav Sharma; Xiaodong Wen; Nesmine R Maptue; Thomas Hever; Craig R Malloy; A Dean Sherry; Chalermchai Khemtong
Journal:  ACS Sens       Date:  2021-11-11       Impact factor: 7.711

4.  Hyperpolarized 13C NMR detects rapid drug-induced changes in cardiac metabolism.

Authors:  Chalermchai Khemtong; Nicholas R Carpenter; Lloyd L Lumata; Matthew E Merritt; Karlos X Moreno; Zoltan Kovacs; Craig R Malloy; A Dean Sherry
Journal:  Magn Reson Med       Date:  2014-08-28       Impact factor: 4.668

5.  The rate of lactate production from glucose in hearts is not altered by per-deuteration of glucose.

Authors:  Alexander M Funk; Brian L Anderson; Xiaodong Wen; Thomas Hever; Chalermchai Khemtong; Zoltan Kovacs; A Dean Sherry; Craig R Malloy
Journal:  J Magn Reson       Date:  2017-09-18       Impact factor: 2.229

6.  Mass isotopomer study of anaplerosis from propionate in the perfused rat heart.

Authors:  Takhar Kasumov; Andrea V Cendrowski; France David; Kathryn A Jobbins; Vernon E Anderson; Henri Brunengraber
Journal:  Arch Biochem Biophys       Date:  2007-03-12       Impact factor: 4.013

7.  Ethanol inhalation on 1-[14C]-pyruvate kinetics in mice using a six-compartment closed model.

Authors:  G Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Apr-Jun       Impact factor: 2.569

8.  Secretion of pyruvate. An antioxidant defense of mammalian cells.

Authors:  J O'Donnell-Tormey; C F Nathan; K Lanks; C J DeBoer; J de la Harpe
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.